GLP-1 Meds Cut Heart Risks in Obesity, Autoimmune Cases
A new study presented at the American Diabetes Association sessions indicates that GLP-1RA medications reduce the risk of serious cardiac events in patients with both obesity and autoimmune diseases. The research suggests these drugs provide cardiovascular benefits beyond weight loss and blood sugar management.
Why it matters
Provides significant clinical evidence for expanding the use of GLP-1RA drugs to high-risk patient populations with autoimmune conditions.
DALLAS, JUNE 6, 2026 - Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association. This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans on Saturday, June 6 at 12:30 p.m. CT/1:30 p.m. CT, abstract number 2199-P.
Scientific reporting based on peer-reviewed research and conference presentations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in